J Korean Acad Rehabil Med.  2007 Dec;31(6):762-766.

The Combination Therapy of Low Dose Estrogen and Fluoride (Monofluorophosphate) for 2 Years in Postmenopausal Women with Osteopenia

• Kim GC
• Jeong HJ

Abstract

OBJECTIVE
To investigate the changes of BMD (bone mineral density), biochemical bone markers and lipid profiles after combination therapy of low dose estrogen (0.3 mg) and intermittent fluoride (monofluorophosphate) in postmenopausal osteopenia. METHOD: We studied 61 women with postmenopausal osteopenia from March 2002 to May 2005. Group I (n=30) was treated with low dose estrogen (0.3 mg), fluocalcic(R) (monofluorophosphate 100 mg+calcium 500 mg), and calcium (500 mg). Group II (n=31) was treated with standard dose estrogen (0.625 mg) and calcium (1,000 mg). BMD at the lumbar spine and femur, osteocalcin, deoxypyridinoline, and lipid profiles were measured at baseline and 2-year after treatment.
RESULTS
1) Average postmenopausal periods were 2.8 years and 3.1 years in Group I and II, respectively. 2) BMD increased significantly in two groups, and BMD in group I increased significantly more than that in group II. 3) Deoxypyridinoline decreased significantly in two groups, and there was no significant difference between the two groups. 4) Total cholesterol and LDL cholesterol decreased significantly in two groups.
CONCLUSION
Combination therapy with monofluorophosphate and low dose estrogen in postmenopausal osteopenia was more effective than standard dose estrogen therapy to prevent postmenopausal osteoporosis.

Keyword

Postmenopausal osteopenia; Monofluorophosphate; Low dose estrogen; Bone mineral density

MeSH Terms

Bone Density
Bone Diseases, Metabolic*
Calcium
Cholesterol
Cholesterol, LDL
Estrogens*
Female
Femur
Fluorides*
Humans
Osteocalcin
Osteoporosis, Postmenopausal
Postmenopause
Spine
Calcium
Cholesterol
Cholesterol, LDL
Estrogens
Fluorides
Osteocalcin